Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 8.1 October 1, 2021
- 8.2 Opinion of Goodwin Procter LLP As to Certain U.S. Federal Tax Matters
- 10.4 Incentive Stock Option Grant Notice
- 10.5 Form of Non-employee Director Compensation Policy
- 10.6 Senior Executive Cash Incentive Bonus Plan
- 10.7 Severance and Change In Control Policy
- 10.8 Amended and Restated Employment Letter Agreement
- 10.9 Employment Letter Agreement
- 10.10 Eric Hedrick, M.D
- 10.12 Amended and Restated Employment Letter Agreement
- 10.13 Founder Agreement
- 10.14 Form of Director Indemnification Agreement
- 10.15 Form of Officer Indemnification Agreement
- 10.16 Lease Agreement
- 10.17 Sublease Agreement
- 10.18 Exclusive License Agreement by and Between Cstone Pharmaceuticals and Eqrx, In
- 10.19 Strategic Collaboration and License Agreement
- 23.1 Consent of Withumsmith+brown, PC
- 23.2 Consent of Ernst & Young LLP
- 99.10 Consent to Reference In Proxy Statement/prospectus
- 99.11 Consent of Houlihan Loukey Capital, Inc.
- Download Excel data file
- View Excel data file
Associated filings
- 2 Dec 21 EFFECT Notice of effectiveness
- 1 Dec 21 424B3 Prospectus supplement
- 30 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Nov 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
1 Oct 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 Aug 21 S-4 Registration of securities issued in business combination transactions
EQRX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-4 Amendment No. 1 of our report dated April 8, 2021, relating to the financial statements of CM Life Sciences III Inc., which is contained in that Prospectus. We also consent the reference to our Firm under the caption “Experts” in the Prospectus.
/s/ WithumSmith+Brown, PC
New York, New York
October 1, 2021